Eli Lilly stock tumbles after new forecasts show weight-loss drug …

Jan 14, 2025  · Eli Lilly stock is down after issuing Q4 2024 guidance that missed Wall Street estimates. ... Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow …


Install CouponFollow Chrome Extension   CouponFollow Extension

$2
OFF

Eli Lilly Stock Tumbles On Lowered Guidance As Weight-Loss Drug …

3 weeks from now

Jan 14, 2025  · The race to develop new weight-loss drugs has been heating up. LLY Stock Technical Ratings Earlier this week, Eli Lilly said it would spend $2.5 billion to acquire a cancer …

investors.com

44%
OFF

Eli Lilly Stock Tumbles On Slower-Than-Expected Weight Loss Drug …

3 weeks from now

Jan 18, 2025  · Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. ... The new forecast from Lilly reflects 44% year-over-year revenue growth for the fourth quarter and …

fool.com

$13
OFF

Eli Lilly Stock Tumbles On Slower-Than-Expected Weight Loss Drug …

3 weeks from now

Eli Lilly now expects revenue to be approximately $13.5 billion for its fourth quarter and $45 billion for the full year 2024. The company had earlier forecast full-year revenue to come in between ...

msn.com

8%
OFF

Lilly Shares On Track For Worst Day Since 2021 After Downbeat …

3 weeks from now

Jan 14, 2025  · (Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time …

yahoo.com

$2
OFF

Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales …

3 weeks from now

The race to develop new weight-loss drugs has been heating up.. LLY Stock Technical Ratings. Earlier this week, Eli Lilly said it would spend $2.5 billion to acquire a cancer drug from …

msn.com

18%
OFF

Novo Nordisk Stock Crashes 18% After New Obesity Drug Misses …

3 weeks from now

Dec 20, 2024  · Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study. ... Eli Lilly stock rose 1.4% to 767.76, …

investors.com

3%
OFF

Eli Lilly Dives On 'Big' Miss For Diabetes, Weight-Loss Drugs

3 weeks from now

Oct 30, 2024  · But on today's stock market, Eli Lilly stock plummeted 6.3% to 846.83. Shares undercut their 200-day line and the lower edge of a flat base with a buy point at 972.53, …

investors.com

38%
OFF

Eli Lilly Stock Soars As FDA Ends Weight Loss Drug Shortage

3 weeks from now

Dec 20, 2024  · How This Affects LLY Stock. LLY investors are celebrating today’s FDA news as it protects Eli Lilly’s sales of its GLP-1 drugs. With that comes an 8.38% increase in share price …

nasdaq.com

35%
OFF

Novo Nordisk And Eli Lilly Rival Soars 35% After Promising Weight …

3 weeks from now

Feb 26, 2024  · Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.

cnbc.com

49%
OFF

Eli Lilly Stock Runs Up 49% Amid Lofty Expectations For Weight …

3 weeks from now

Jun 12, 2024  · Revenue from Eli Lilly's (LLY) weight-loss drug is expected to triple over the next five years. Those lofty Wall Street views have lifted Eli Lilly stock to a record high, as the stock …

investors.com

5%
OFF

Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

3 weeks from now

Jan 24, 2025  · The results line up favorably with Eli Lilly's Zepbound, which at best has shown 22.5% weight loss over 72 weeks. They also appear to outperform Lilly's next-generation drug, …

investors.com

FAQs about Eli Lilly stock tumbles after new forecasts show weight-loss drug … Coupon?

Why did Eli Lilly's stock tumble 8% on Tuesday?

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023. ...

Why did Eli Lilly stock drop in December?

Eli Lilly on Tuesday lowered guidance for its December quarter amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs. Eli Lilly stock tumbled on the news. For the December quarter, the Indianapolis-based company said it expects revenue of about $13.5 billion, below consensus estimates of $13.93 billion. ...

Is Eli Lilly stock a good buy?

Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity? Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. ...

Why did Eli Lilly stock crash Wednesday?

Eli Lilly (LLY) stock crashed Wednesday after the pharma giant cut its 2024 outlook following a "big" miss for its popular diabetes and weight-loss drugs. The company's drug, tirzepatide, provides the backbone for diabetes treatment Mounjaro and weight-loss drug Zepbound. In the September quarter, Mounjaro sales rocketed 121% to $3.11 billion. ...

Why did Eli Lilly stock fall on lowered Q4 guidance?

Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs. ...

Will Eli Lilly stock triple over the next 5 years?

Revenue from Eli Lilly 's ( LLY) weight-loss drug is expected to triple over the next five years. Those lofty Wall Street views have lifted Eli Lilly stock to a record high, as the stock is up 49% this year alone. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension